Economic Evaluation of Ferric Carboxymaltose versus Oral Ferrous Sulphate for Iron Deficiency Anaemia in Pregnancy in Nigeria: A Cost-Utility Analysis
Preprint
- 30 July 2025
- preprint
- Published by F1000 Research Ltd in VeriXiv
Abstract
No abstract availableAll Related Versions
Funding Information
- Bill and Melinda Gates Foundation (INV-017271)
This publication has 30 references indexed in Scilit:
- Intravenous versus oral iron for anaemia among pregnant women in Nigeria (IVON): an open-label, randomised controlled trialThe Lancet Global Health, 2024
- Maternal anaemia and the risk of postpartum haemorrhage: a cohort analysis of data from the WOMAN-2 trialThe Lancet Global Health, 2023
- Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000–2019)Annals of Hematology, 2023
- Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trialThe Lancet, 2023
- Population health outcomes in Nigeria compared with other west African countries, 1998–2019: a systematic analysis for the Global Burden of Disease StudyThe Lancet, 2022
- The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A ReviewValue in Health, 2022
- Severity of Anemia During Pregnancy and Adverse Maternal and Fetal OutcomesJAMA Network Open, 2022
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task ForceValue in Health, 2022
- Iron deficiencyThe Lancet, 2021
- Comparison of Economic Evaluation Methods Across Low‐income, Middle‐income and High‐income Countries: What are the Differences and Why?Health Economics, 2016